ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

BACKGROUND: The role of adjuvant chemotherapy and the value of molecular biomarkers in bladder cancer have not been determined. We aimed to assess the predictive and prognostic values of excision repair cross-complementation 1 (ERCC1) in identifying appropriate patients who may potentially benefit f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sun, Jong-Mu, Sung, Ji-Youn, Park, Se Hoon, Kwon, Ghee Young, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Jo, Jisuk, Choi, Han Yong, Lim, Ho Yeong
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3404914/
https://ncbi.nlm.nih.gov/pubmed/22616552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-187
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados